Table 1

Patient demographics and disease characteristics at baseline (prior to commencement of TNFi)

Cohort size43
Age at study entry (SD)38.9 (11.6)
Female gender2762.8
Bilateral disease3172.3
Median duration of disease prior to biologic therapy, years (IQR)3.0 (7.0)
Anatomical classification of ocular disease
 Anterior uveitis37
 Intermediate uveitis818.6
 Posterior uveitis1534.9
 Systemic vasculitis12.3
 Ankylosing spondylitis12.3
 Juvenile idiopathic arthritis24.6
 Juvenile sarcoidosis12.3
 Psoriatic arthropathy24.6
 Undifferentiated arthritis12.3
Visual acuity logMAR score
 >0.1, ≤0.31841.8
 >0.3, ≤1920.9
Clinical disease activity
 Anterior chamber inflammation ≥1+716.3
 Cystoid macular oedema (active inflammation)9*20.9
 Vitreous haze score ≥1511.6
 Retinal vasculitis2353.5
 Choroidal inflammation24.6
 Missing data0
 Ocular hypertension24.6
 Epiretinal membrane1432.6
 Retinal ischaemia within the macula818.6
 Retinal ischaemia within peripheral retina1227.9
  • *Missing data for one patient.

  • TNFi, tumour necrosis factor-alpha inhibitor; logMAR, logarithm of the minimum angle of resolution.